Poison pill ruling may weaken French targets
Aventis and Sanofi-Synthelabo are set to merge after a tense three-month standoff. But at what price? Megan Murphy looks at whether a regulatory decision could leave French companies more vulnerable to takeover
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: